In Vitro Diagnostics - Northern Europe

  • Northern Europe
  • The projected revenue for the In Vitro Diagnostics market market in Northern Europe is estimated to be US$1.22bn in 2024.
  • This market is expected to grow at an annual growth rate (CAGR 2024-2029) of 2.50%, leading to a market volume of US$1.38bn by 2029.
  • In comparison to other countries worldwide, the United States is anticipated to generate the highest revenue with US$30,100.00m in 2024.
  • In Northern Europe, the market for In Vitro Diagnostics is experiencing significant growth due to the region's strong focus on healthcare innovation and investment in advanced medical technologies.

Key regions: China, France, Japan, Netherlands, Italy

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The In Vitro Diagnostics market in Northern Europe is experiencing steady growth and development, driven by customer preferences, trends in the market, local special circumstances, and underlying macroeconomic factors. Customer preferences in Northern Europe are shifting towards more personalized and preventive healthcare, leading to an increased demand for In Vitro Diagnostics. Patients are becoming more proactive in managing their health and are seeking diagnostic tests that can provide early detection and accurate results. Additionally, there is a growing focus on non-invasive and point-of-care testing, as it offers convenience and faster results. Trends in the market are also contributing to the development of the In Vitro Diagnostics market in Northern Europe. Technological advancements have led to the introduction of innovative diagnostic tests that are more accurate, reliable, and cost-effective. This has increased the adoption of In Vitro Diagnostics in various healthcare settings, including hospitals, clinics, and laboratories. Furthermore, there is a rising demand for molecular diagnostics and genetic testing, as they provide valuable insights into an individual's risk of developing certain diseases and help in personalized treatment planning. Local special circumstances in Northern Europe, such as an aging population and a high prevalence of chronic diseases, are driving the demand for In Vitro Diagnostics. The region has a growing elderly population, which is more susceptible to age-related diseases and requires regular diagnostic monitoring. Moreover, the high incidence of chronic diseases, such as diabetes and cardiovascular diseases, necessitates regular diagnostic testing for disease management and prevention. Underlying macroeconomic factors, such as increasing healthcare expenditure and favorable government initiatives, are supporting the growth of the In Vitro Diagnostics market in Northern Europe. Governments in the region are investing in healthcare infrastructure and promoting the adoption of advanced diagnostic technologies. This is driving the market growth by increasing accessibility to diagnostic services and encouraging healthcare providers to invest in state-of-the-art diagnostic equipment. In conclusion, the In Vitro Diagnostics market in Northern Europe is developing due to customer preferences for personalized and preventive healthcare, trends in the market such as technological advancements and increased demand for molecular diagnostics, local special circumstances such as an aging population and high prevalence of chronic diseases, and underlying macroeconomic factors including increasing healthcare expenditure and government initiatives. This growth is expected to continue as the healthcare landscape in the region evolves and the demand for accurate and efficient diagnostic tests continues to rise.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on medical devices and IVD revenues allocated to the country where the money is spent at manufacturer price levels excluding VAT.

Modeling approach / Market size:

Modeling employs a top-down approach with a bottom-up validation, using financial information of the key players by market. Market sizes are determined by a top-down approach, based on a specific rationale for each market market and allocated to the covered countries according to the global market shares. As a basis for evaluating markets, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare system, and regulations concerning medical products. Next, we use further relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare payer system, and regulations concerning medical products. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.

Overview

  • Revenue
  • Key Players
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)